Form 4: Gilead Sciences Director Javier Rodriguez Reports Stock and Option Awards

Director Javier Rodriguez reports acquisition of restricted stock units and stock options in Gilead Sciences.

Summary

• Javier Rodriguez, a director of Gilead Sciences, reported a transaction on May 7, 2025.
• Rodriguez acquired 1,516 shares of common stock through restricted stock units (RSUs) under the 2022 Equity Incentive Plan, which vested immediately.
• He also acquired 6,809 shares via non-qualified stock options with an exercise price of $98.90, which also vested immediately and expire on May 7, 2035.
• Following the reported transactions, Rodriguez beneficially owns 12,218 shares of common stock and 6,809 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it reflects standard compensation practices. The immediate vesting is a slightly positive signal.

Positives

• The immediate vesting of both the RSUs and stock options suggests confidence in the director's continued contribution and the company's future performance.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which can be an indicator of management's sentiment towards the company's prospects.

Comparison to Industry Standards

• Stock option and RSU grants are a common form of executive compensation in the pharmaceutical industry, used by companies like Amgen, Pfizer, and Johnson & Johnson to align management interests with shareholder value.
• The vesting schedules and grant sizes are typically benchmarked against peer companies to ensure competitiveness and retention.

Stakeholder Impact

• The grant of equity to a director aligns their interests with those of shareholders.
• This can incentivize the director to make decisions that increase shareholder value.

Key Dates

Keywords

Gilead Sciences, Director, Rodriguez, Stock Options, RSUs, Form 4, Beneficial Ownership, Equity Incentive Plan